🚀 VC round data is live in beta, check it out!
Opsy Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for Opsy Holding and similar public comparables like Liminatus Pharma, Alzinova, Pure Biologics, CalciMedica and more.
Opsy Holding Overview
About Opsy Holding
Opsy Holding AB is a Swedish tech company that develops solutions at the intersection of medicine and insurance. The group assures, optimizes, and modernizes handling illnesses, accidents, and personal injuries. It's platform OpsyOne, develop and automates claims settlement processes to increase precision, transparency, and efficiency.
Founded
2007
HQ
Employees
2
Website
Sectors
Financials (FY)
EV
$10M
Opsy Holding Financials
Opsy Holding reported last fiscal year revenue of $728K and negative EBITDA of ($1M).
In the same fiscal year, Opsy Holding generated $908K in gross profit, ($1M) in EBITDA losses, and had net loss of ($2M).
Opsy Holding P&L
In the most recent fiscal year, Opsy Holding reported revenue of $728K and EBITDA of ($1M).
Opsy Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $728K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $908K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 125% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($1M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (180%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (256%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (258%) | XXX | XXX | XXX |
| Net Debt | — | — | $20K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Opsy Holding Stock Performance
Opsy Holding has current market cap of $10M, and enterprise value of $10M.
Market Cap Evolution
Opsy Holding's stock price is $0.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10M | $10M | -0.5% | XXX | XXX | XXX | $-0.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOpsy Holding Valuation Multiples
Opsy Holding trades at 13.9x EV/Revenue multiple, and (7.7x) EV/EBITDA.
Opsy Holding Financial Valuation Multiples
As of April 19, 2026, Opsy Holding has market cap of $10M and EV of $10M.
Equity research analysts estimate Opsy Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Opsy Holding has a P/E ratio of (5.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10M | XXX | $10M | XXX | XXX | XXX |
| EV (current) | $10M | XXX | $10M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 13.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (7.7x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (5.4x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 11.1x | XXX | XXX | XXX |
| P/E | — | XXX | (5.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 39.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Opsy Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Opsy Holding Margins & Growth Rates
Opsy Holding's revenue in the last fiscal year grew by —.
Opsy Holding's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $1.4M for the same period.
Opsy Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Margin | — | XXX | (180%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (73%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.4M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 381% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Opsy Holding Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Opsy Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Liminatus Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Alzinova | XXX | XXX | XXX | XXX | XXX | XXX |
| Pure Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| CalciMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Chosa Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Opsy Holding M&A Activity
Opsy Holding acquired XXX companies to date.
Last acquisition by Opsy Holding was on XXXXXXXX, XXXXX. Opsy Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Opsy Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOpsy Holding Investment Activity
Opsy Holding invested in XXX companies to date.
Opsy Holding made its latest investment on XXXXXXXX, XXXXX. Opsy Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Opsy Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Opsy Holding
| When was Opsy Holding founded? | Opsy Holding was founded in 2007. |
| Where is Opsy Holding headquartered? | Opsy Holding is headquartered in Sweden. |
| How many employees does Opsy Holding have? | As of today, Opsy Holding has over 2 employees. |
| Is Opsy Holding publicly listed? | Yes, Opsy Holding is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Opsy Holding? | Opsy Holding trades under OPSYH ticker. |
| When did Opsy Holding go public? | Opsy Holding went public in 2010. |
| Who are competitors of Opsy Holding? | Opsy Holding main competitors are Liminatus Pharma, Alzinova, Pure Biologics, CalciMedica. |
| What is the current market cap of Opsy Holding? | Opsy Holding's current market cap is $10M. |
| What is the current revenue of Opsy Holding? | Opsy Holding's last fiscal year revenue is $728K. |
| What is the current EV/Revenue multiple of Opsy Holding? | Current revenue multiple of Opsy Holding is 13.9x. |
| Is Opsy Holding profitable? | No, Opsy Holding is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.